Make the award decision about demonstrated capability
Two lyophilizer quotations offer the same shelf area and nominal condenser ice capacity. One costs less; the other promises a shorter cycle and comprehensive qualification support. Neither comparison is decision-ready until the team knows the conditions behind the claims. Shelf area does not define usable batch capacity, and a short demonstration cycle does not establish performance for the intended products.
The procurement objective is to select a supplier whose equipment, evidence and lifecycle support fit the site's product and manufacturing strategy. Begin with an approved user requirements specification and a clear division of responsibilities. Identify the product families, containers, load range, aseptic interfaces, utilities, space constraints and intended automation connections.
Keep the evaluation vendor-neutral. Ask each bidder to respond against the same requirements, disclose assumptions and identify exceptions. A detailed compliance matrix is more useful than a general declaration of GMP suitability. The purchasing decision should remain traceable when engineering, quality or the commercial programme later asks why a particular capability or contractual exclusion was accepted.
Give bidders a usable product and process basis
The request for proposal should describe the intended operating envelope without disclosing unnecessary proprietary formulation detail. Provide relevant container formats, fill ranges, batch configurations, expected thermal demands and known process constraints. Distinguish established requirements from development uncertainties. If product data are incomplete, ask how the supplier will support capability assessment and manage that uncertainty.
Explain whether cycles are established, under development or expected to transfer from another scale. Include the anticipated range of freezing, primary-drying and secondary-drying demands, with references to approved development information where available. Do not turn typical temperatures or pressures from unrelated products into procurement requirements.
Define the intended manufacturing workflow: filling-to-loading transfer, loading method, access, sterilization, unloading and final closure. Document product-contact and sterile-boundary responsibilities, along with interfaces to the building, barriers and utilities. A bidder cannot reliably price or guarantee an interface that remains unspecified. Open assumptions tend to reappear later as variations, schedule delays or qualification gaps.
Evaluate chamber, shelves and loading as one system
Review usable shelf area with the actual vial arrangement, edge clearance, loading frame and stoppering configuration. Compare nominal capacity with the number of containers that can be handled and processed in the approved pattern. Ask how minimum and partial loads are addressed; the largest load is not necessarily the most demanding for every product risk.
Examine shelf construction, thermal-fluid distribution, temperature measurement, ramp behaviour and access for cleaning or maintenance. Ask which performance claims concern the fluid, the shelf surface or a loaded condition. Uniformity claims need defined measurement locations, stabilization conditions and uncertainty. A brochure number without those conditions is not an acceptance criterion.
For loading and unloading, assess transfer protection, alignment, interventions, recovery from jams and consequences of incomplete stoppering. Compare automatic and manual approaches through the site's contamination-control and operational needs. Mechanical stoppering capability and container closure integrity remain separate questions. Require the supplier to state what it demonstrates and what product-package studies remain the manufacturer's responsibility.
Challenge condenser, vacuum and refrigeration claims
Ask for separate evidence of total ice storage and instantaneous vapour-handling capability. The latter depends on refrigeration, condenser conditions and the path between chamber and condenser. Valve and duct geometry can constrain transport before the stated ice capacity is reached. Compare capability at relevant operating conditions rather than accepting a single headline value.
Evaluate the vacuum system as a controlled process function. Distinguish empty-chamber pump-down, chamber integrity and pressure regulation under vapour load. Review sensor principles and locations, controlled gas bleed, valve response, pump configuration and failure handling. An ultimate pump pressure does not describe loaded process control or the suitability of the sterile boundary.
For refrigeration, request performance assumptions for available site utilities, ambient conditions and simultaneous demands. Examine redundancy by failure scenario: an additional compressor does not automatically provide uninterrupted process capability. Review refrigerant availability, service competence and applicable environmental obligations in the installation jurisdiction. Require a documented lifecycle strategy instead of assuming that today's component availability guarantees future support.
Assign aseptic, cleaning and sterilization interfaces
[REGULATORY REQUIREMENT] Where EU sterile GMP applies, Annex 1 places lyophilization within the aseptic chain. Procurement should enable the applicable controls for protected transfers, sterilization, chamber integrity and loading patterns. The equipment supplier's scope must align with the site's contamination control strategy and the responsibilities of barrier and filling-line suppliers.
Request a clear sterilization boundary drawing and identify valves, filters, drains, sensors and connected paths included in the design. Examine cleanability, drainage, cleaning coverage, sterilization conditions, post-sterilization protection and maintenance access. Cleaning removes residues; sterilization addresses viable contamination. Neither activity can be assumed to demonstrate the other.
Agree who develops and executes the relevant cleaning and sterilization studies, who supplies instruments and documentation, and how interface failures will be resolved. The specific Annex 1 chamber-leakage check at each cycle start requires an implementable, qualified arrangement and a justified acceptance limit. Do not accept a generic “SIP ready” statement as closure of these design and evidence obligations.
Evaluate automation as a maintainable regulated system
Ask the supplier to demonstrate recipe management, phase transitions, alarm handling, interlocks, aborts and restart logic using relevant scenarios. Compare how the system records the executed configuration and operator actions. A screen demonstration of a normal cycle is insufficient to assess whether a disrupted batch can be reconstructed reliably.
Review access control, audit trails, time synchronization, data retention, backup restoration and interfaces to historians or batch-record systems. Define ownership and access to configuration, licenses and essential documentation. Where remote support is proposed, specify authorization, session control, change recording and recovery arrangements compatible with the site's policies.
[REGULATORY REQUIREMENT] Assess computerized-system responsibilities against applicable Annex 11 and other relevant requirements. Its operational edition must be distinguished from consultation drafts. Supplier software testing can contribute evidence, but the manufacturer retains responsibility for the validated intended use. Require an explicit support and obsolescence policy covering operating systems, controller hardware, security updates and the impact of upgrades on validated configurations.
Compare qualification support through deliverables
“Full validation support” is too ambiguous for contract acceptance. List the expected deliverables: design documents, calculations where relevant, material records, instrument lists, calibration evidence, functional specifications, test protocols, raw results, deviations, software versions, manuals and turnover documentation. Define language, format, review cycles, ownership and delivery milestones.
Specify the purpose and conditions of factory and site acceptance testing. Agree which functions can be verified at the factory, which depend on installed utilities and which evidence may support subsequent qualification. Annex 15 allows justified use of appropriate factory evidence where its validity is preserved. That requires traceability and access to the underlying records, not merely a supplier certificate.
Ask how the supplier handles failed tests, design changes and retesting. Define responsibilities for representative loads, test equipment, travel, consumables and repeat attendance. Product process validation, aseptic simulation and container closure studies should not disappear between equipment and pharmaceutical scopes. Identify the supporting contribution from the supplier without assigning it responsibility for conclusions outside the agreed work.
Score evidence before weighting preferences
Separate mandatory eligibility criteria from scored preferences. An unresolved critical requirement should not be hidden by a high score for price, delivery or presentation quality. For each criterion, record the evidence, confidence level, assumptions and unresolved clarification. Apply agreed weights only after the team understands what the scores represent.
| Evaluation domain | Evidence requested | Decision concern |
|---|---|---|
| Process capability | Relevant loaded tests and stated conditions | Can the equipment serve the intended process range? |
| Aseptic integration | Boundary drawings and interface responsibilities | Are protection and verification gaps closed? |
| Automation and records | Scenario demonstration and lifecycle documentation | Can intended use remain controlled and reconstructable? |
| Qualification | Deliverable register and traceable test evidence | Is support concrete enough for acceptance? |
| Service and spares | Named coverage, response model and availability | Can faults be diagnosed and corrected locally? |
| Lifecycle cost | Explicit assumptions and sensitivity cases | Are apparent savings robust to operating uncertainty? |
This original matrix supports a project-specific evaluation. It does not rank brands or prescribe universal weights. Involve process development, engineering, quality, production, automation and maintenance so that commercial scoring does not conceal an unresolved technical consequence.
Build TCO around operating scenarios
Total cost of ownership should include more than purchase price. Consider installation, utilities, facility modifications, qualification, cycle-development support, licenses, maintenance, calibration, spares, consumables, energy, planned downtime and eventual upgrades. Define the analysis period and financial assumptions with the organization rather than selecting a universal horizon or discount rate.
Model realistic production scenarios. Batch throughput depends on loading, preparation, sterilization, freezing, drying, unloading, cleaning and availability, not only the shortest drying phase quoted. Product mix, campaigns, changeovers and service response can dominate the economic comparison. Avoid monetizing an unverified cycle-time promise as if it were a contractual guarantee.
Use sensitivity cases for uncertain inputs such as utilization, energy demand, repair duration and spare-parts lead time. Record which costs are quoted, estimated or excluded. A supplier with a higher initial price may offer lower cost in one scenario and higher cost in another. Present those dependencies to the decision-makers instead of compressing uncertainty into a deceptively precise single total.
Examine the service promise through a credible fault scenario. Ask who can diagnose a refrigeration problem, who may access the control system, which parts are stocked and when a trained technician can attend. Distinguish acknowledgement of a support request from restoration of operation. Confirm whether travel, specialist labour, software investigation and qualification support after repair are included. A response-time statement with undefined coverage can look reassuring while leaving the principal downtime risk with the site.
Example: equal capacity, different contractual exposure
Consider two illustrative bids with the same nominal shelf area. Bid A provides an attractive equipment price and an empty-chamber acceptance test. Bid B costs more and includes a defined loaded capability demonstration, site utility assumptions, raw test data and support for interface qualification. The commercial comparison initially treats the difference as an expensive documentation package.
The technical review finds that Bid A excludes loaded pressure-control performance and repeat attendance if site utilities require adjustment. Its service model also relies on overseas specialist availability. These facts do not automatically disqualify the offer, but they change both risk and cost. The team requests an aligned scope and evaluates the remaining exclusions explicitly.
After clarification, the decision uses comparable deliverables and scenarios. If an exclusion is retained, its owner, financial allowance and evidence plan are approved. The lesson is to compare the capability and responsibilities actually purchased. A low price is meaningful only when the organization understands which work and uncertainty it will retain.
The final record should also explain why rejected alternatives were not selected. Preserve the original bids and the agreed revisions so that later negotiations cannot erase an assumption essential to the award decision.
Convert the selection into enforceable handover criteria
Before award, close critical clarifications and incorporate agreed responses into the contract. Identify performance guarantees, test conditions, exclusions, change procedures and consequences of nonconforming results. Define what constitutes mechanical completion, site acceptance, documentation turnover and readiness for the next qualification stage. Do not let a shipment date stand in for demonstrated readiness.
Use a final decision checklist:
- Product, container, load and utility assumptions are explicit and approved.
- Capacity claims distinguish thermal, vacuum, vapour-flow and ice-storage performance.
- Aseptic, cleaning, sterilization and automation interfaces have named owners.
- Acceptance tests, raw evidence and retest responsibilities are defined.
- Service coverage, critical spares and obsolescence commitments are credible.
- TCO assumptions and contractual exclusions are visible to the approving team.
The supplier relationship continues after handover. Establish escalation routes, maintenance support, configuration control and performance-review arrangements. Treat future refrigerant changes, software migrations or equipment retrofits as changes requiring impact assessment. A well-selected supplier contributes evidence and technical support throughout that lifecycle; the pharmaceutical manufacturer remains accountable for the suitability and control of its manufacturing process.
Sources and scope
Sources checked on 26 September 2026. Apply requirements within their jurisdiction and scope. Scientific evidence and engineering recommendations do not establish universal cycle settings. Examples are illustrative. For licensed documents, only public scope and edition were verified; research access limitations are recorded in the source register.
- EU GMP Annex 1 — Manufacture of Sterile Medicinal Products — Revision 2022 — Regulatory requirement.
- EU GMP Annex 15 — Qualification and Validation — 2015 revision — Regulatory requirement.
- EU GMP Annex 11 — Computerised Systems — Revision 1, January 2011 — Regulatory requirement.
- ICH Q9(R1) — Quality Risk Management — EMA Step 5 Revision 2, Corr.2; ICH revision R1 — Quality risk management.
- ICH Q10 — Pharmaceutical Quality System — Step 5 — Guidance.
- Freeze-Drying Process Development and Scale-Up: Scale-Up of Edge Vial Versus Center Vial Heat Transfer Coefficients, Kv (2016) — Scientific principle.
- Freeze-Dryer Equipment Capability Limit: Comparison of Computational Modeling With Experiments at Laboratory Scale (2019) — Scientific principle.
- Equipment Capability Measurement of Laboratory Freeze-Dryers: a Comparison of Two Methods (2021) — Scientific principle.
- From laboratory to production: a journey of GMP implementation for controlled ice nucleation in Amgen’s manufacturing network (2026) — Scientific principle.
